Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03038022
Study type Interventional
Source Madrigal Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 2
Start date February 9, 2017
Completion date January 15, 2018

See also
  Status Clinical Trial Phase
Completed NCT03563547 - Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia N/A
Terminated NCT03694197 - Long Term Safety Study of PRALUENT Phase 4
Active, not recruiting NCT04759534 - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia Phase 3
Completed NCT01968980 - A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia Phase 3
Completed NCT00171236 - Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia Phase 3
Completed NCT03397121 - Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) Phase 3
Completed NCT04173793 - A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Phase 2
Not yet recruiting NCT06164730 - A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease Phase 1
Completed NCT02326220 - Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy Phase 3
Completed NCT02392559 - Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders Phase 3
Completed NCT02460159 - A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) Phase 3
Terminated NCT01583647 - A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) Phase 1
Active, not recruiting NCT05398029 - A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease Phase 1
Completed NCT00706849 - Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease Phase 3
Completed NCT04666298 - Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C Phase 2
Completed NCT01515241 - Exploratory Study of Plaque Regression Phase 2
Completed NCT01576484 - Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) Phase 2
Terminated NCT00151788 - Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE. Phase 2/Phase 3
Completed NCT05325203 - A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). Phase 3
Completed NCT01709500 - Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) Phase 3